Inflammatory/Immune Adverse Events in Chronic Myeloid Leukemia Patients During Treatment With Bosutinib.

ABSTRACT:

Background

Bosutinib, a tyrosine kinase inhibitor (TKI), is effective in treating chronic myeloid leukemia (CML) patients resistant or intolerant to previous TKIs. Unlike other TKIs, bosutinib's lack of inhibition of c-KIT and PDGFR may contribute to its unique tolerability profile. Similar to dasatinib, it targets Bcr/Abl and SRC kinases, particularly Lyn, raising safety concerns. In fact, the susceptibility of Lyn -/- mice to autoimmune disorders and the deregulation of Lyn-dependent pathways in patients with lupus were previously shown.

Aims

This study aimed to assess the time-adjusted rate (TAR) of inflammatory/immune-related adverse events in bosutinib-treated patients.

Methods

We analyzed clinical data from 60 patients with a minimum follow-up of three months. W

SUBMITTER: Agostani E 

PROVIDER: S-EPMC11799592 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature